Osmotic controlled drug delivery system (OSMO technology) and its impact on diabetes care

Rajesh Rajput, K. M. K. Prasanna Kumar, D. S. Arya, A. K. Das, A. H. Zargar, Mangesh Tiwaskar, Vijay Motghare, Ruchi Shah, Shahu Ingole, Rishi Jain


Recently, focus on the development of controlled release drug delivery system has increased, as existing drugs exhibit certain pharmacokinetic limitations. The major goal of designing sustained release formulations is to improve the drug performance by prolonged duration of drug action, decreased frequency of dosing and reduced side effects by using smallest quantity of drug administered by the most suitable route. Osmotic-controlled release oral delivery system (OSMO technology) is the most promising strategy based system for sustained delivery of drug. Drug can be delivered in a controlled manner over a long period of time by the process of osmosis. Osmotic drug delivery system appears to be a promising solution for the limitations of conventional extended release formulations by virtue of their distinguished technological features. The present review describes briefly about various controlled drug delivery systems with special focus on advantages of osmotic-controlled release oral delivery system related to diabetes therapy and improved compliance.


Osmo technology, Controlled drug delivery, Sustained release, Metformin gastrointestinal intolerability, Adherence

Full Text:



Deepika B, Sameen S, Nazneen N, Madhavi A, Kandukoori NR, Dutt KR. Matrix drug delivery system-a review. Eur J Pharm Med Res. 2018;5(2):150-4.

Patel H, Patel U, Kadikar H, Bhimani B, Daslaniya D, Patel G. A Review On Osmotic Drug Delivery System. IRJP. 2012;3(4):88-94.

Jain KK. Drug delivery systems. 1st edition. Switzerland: Humana Press. 2008;1-51.

Paul B, Gupta PK, Ara HD, John EH. Remington the science and practice of pharmacy. 21st edition. New York: Wolter kluwer, Lippincott wiliams and Wilkins. 2006;939-62.

Edith M. Encyclopedia of controlled drug delivery. 1st edition. New York: A wiley interscience publication. 2009;381-5.

Gilbert SB, Christopher TR. Modern pharmaceutics. 3rd edition revised and expanded. New York: Marcel Dekker Inc. 1995;575-608.

Sahilhusen IJ, Mukesh RP, Alpesh DP. Sustained release drug delivery systems: a patent overview. Aperito J Drug Designing and Pharmacology. 2014;1(1):1-4.

Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug delivery. 2016;23(7):2371-90.

Ghosh T, Ghosh A. Drug delivery through osmotic systems—an overview. J Appl Pharm Sci. 2011;1(2):38-49.

Khatri N, Nikam S, Bilandi A. IJPSR. 2016;7(6):2302-12.

Pandey S, Devmurari V. Osmotic pump drug delivery devices: from implant to sandwiched oral therapeutic system. Int J Pharm Technol Res. 2010;2:693-9.

Mathur M, Mishra R. A review on osmotic pump drug delivery system. Int J Phar Sci and Res. 2016;1(7):453-67.

Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opinion. 2006;22(10):1879-92.

Gupta BP, Thakur N, Jain NP, Banweer J, Jain S. Osmotically controlled drug delivery system with associated drugs. J Pharm Pharmaceutic Sci. 2010;13(4):571-88.

Keraliya RA, Patel C, Patel P, Keraliya V, Soni TG, Patel RC, Patel MM. Osmotic drug delivery system as a part of modified release dosage form. ISRN pharmaceutics. 2012;1-9.

Malaterre V, Ogorka J, Loggia N, Gurny R. Oral osmotically driven systems: 30 years of development and clinical use. Eur J Pharm Biopharm. 2009;73(3):311-23.

Sowjanya M, Rao VP, Babu PS, Pallavi K. Osmotic Drug Delivery Systems: A Review. Inventi Rapid: NDDS. 2017;3:1-9.

Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabet Ther. 2013;4(2):175-94.

Sankar UV, Lipska K, Mini GK, Sarma PS, Thankappan KR. The adherence to medications in diabetic patients in rural Kerala, India. Asia Pacific J Public Health. 2015;27(2):513-23.

Sontakke S, Jadhav M, Pimpalkhute S, Jaiswal K, Bajait C. Evaluation of adherence to therapy in patients of type 2 diabetes mellitus. J Young Pharm. 2015;7(4):462.

Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Advances in Ther. 2014;31(12):1287-305.

Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opinion. 2013;29(10):1275-86.

Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient preference and adherence. 2013;7:525-30.

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient preference and adherence. 2016;10:1299-307.

Serial Medication Nonadherence in Patients with Type 2 Diabetes. Am Health Drug Benefits. 2015;8(2):S12-S16.

Luga AO, McGuire MJ. Adherence and health care costs. Risk management and healthcare policy. 2014;7:35.

Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279-84.

Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabet Ther. 2019;10(1):5-19.

Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabet Care. 2006;29(4):759-64.

Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opinion. 2004;20(4):565-72.

Data on file (Executive Summary for Vildagliptin SR tablets 50 mg)

Data on file (PK-PD data for Metformin OSMO tablet 1000mg).